800-826-HOPE (4673)

If you have been recently diagnosed with lung cancer or looking for a second opinion, you and your family may be facing a lot of difficult questions. City of Hope's lung cancer specialists can walk you through the treatment process, address your concerns, and create a personalized plan designed to give you the best possible results.

Why Choose Us

We bring together treatment and research expertise from multiple disciplines with an unmatched reputation for coordinated, compassionate care:

Request an appointment online or contact us at 800-826-HOPE (4673). Please visit Making Your First Appointment for more information.

Top Ranked Cancer Center

  • Recognized internationally for research and breakthrough treatments
  • Designated a Comprehensive Cancer Center by the National Cancer Institute
  • Named by U.S. News & World Report as one of America's top cancer hospitals for over a decade

Learn More About Lung Cancer

Care Team

City of Hope’s renowned thoracic physicians and researchers utilize the latest in technology and innovation to treat lung cancer, coupled with our enduring belief in providing unparalleled compassionate care. Call 800-826-HOPE or request an appointment online.

Thoracic Surgery

Loretta Erhunmwunsee, M.D.

Clinical Specialties

  • Thoracic Surgery
Jae Y. Kim, M.D.

Clinical Specialties

  • Thoracic Surgery
Dan J. Raz, M.D., M.A.S.

Clinical Specialties

  • Thoracic Surgery

Medical Oncology

Samuel W. Chung, M.D.

Clinical Specialties

  • Medical Oncology
  • Hematology
Mihaela C. Cristea, M.D.

Clinical Specialties

  • Medical Oncology
M. Houman Fekrazad, M.D.

Clinical Specialties

  • Medical Oncology
Karen Reckamp, M.D., M.S.

Clinical Specialties

  • Medical Oncology
Ravi Salgia, M.D., Ph.D.

Clinical Specialties

  • Medical Oncology

Radiation Oncology

Sagus Sampath, M.D.

Clinical Specialties

  • Radiation Oncology

Hematology, Pathology, and Diagnostic Radiology

Marianna Koczywas, M.D.

Clinical Specialties

  • Medical Oncology
Tommy Tong, M.D.

Clinical Specialties

  • Anatomic & Clinical Pathology
Arnold J. Rotter, M.D.

Clinical Specialties

  • Diagnostic Radiology
Emily Taylor Success Story Image
Emily, lung cancer survivor

With the burden of cancer greatly lifted, the Taylors are now embarking on their next big adventure of building a family.

At City of Hope, we design a personalized lung cancer treatment plan just for you. We support you every step of the way, both during treatment and after, helping you and your loved ones manage your recovery.

Our entire team works together to bring you options that will deliver the best outcome possible:

Why Picking The Right Center For Lung Cancer Screening Matters

Dan Raz, M.D., M.A.S., co-director of City of Hope's Lung Cancer and Thoracic Oncology Program, on why it matters where you have your lung cancer screening done.

Advanced Lung Cancer Treatment

Karen Reckamp, M.D., M.S., co-director of the Lung Cancer and Thoracic Oncology Program, discusses lung cancer treatment at City of Hope.



City of Hope is a recognized leader in lung cancer research. There is extensive collaboration between lung cancer clinicians and researchers develop and evaluate new therapies designed to improve survival and quality of life outcomes. City of Hope patients have access to a wide variety of clinical trials ranging from new chemotherapy and targeted therapies, hormone therapies, novel surgical techniques and new radiation approaches - all focused on enhancing lung cancer treatment, detection and prevention.

Some of our current research projects include:

  • Our researchers are currently studying markers of metastatic potential within lymph nodes of patients with completely resected non-small cell lung cancer (NSCLC). This allows them to better understand how the tumor and the immune system interact to facilitate cancer spread. By understanding these mechanisms, targeted molecules can then be developed to block tumor metastasis and improve survival.
  • As we gain knowledge into the biology of lung cancer, our clinicians have also incorporated the evaluation of biomarkers into our trials to better tailor therapies to our patients, particularly those with advanced disease.
  • The signaling pathway cyclooxygenase-2 (COX-2) plays a key role in lung tumor growth, spread and therapy resistance, so our researchers developed a drug trial to see if the COX-2 inhibitor, celecoxib, can improve outcomes by enhancing the effectiveness of another lung cancer drug.
  • Patients with advanced lung cancer frequently have immune system abnormalities, including depletion of the B cells and T cells, which make up the body’s defense system. Our researchers have identified a compound in shiitake mushrooms called beta-glucans that can enhance immune system activity, and City of Hope is conducting a trial to see if it can slow or halt tumor growth in lung cancer patients.
  • Because lung cancer patients are often present with advanced disease that compromises their quality of life, City of Hope researchers are continually investigating and implementing interventions that can support patients and their families through supportive and palliative care.

  • A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects with Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
  • Utilization and Perceptions of Lung Cancer Screening Among Primary Care Physicians
  • TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single Subject-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy
  • A Phase Ib Parallel Cohort Study Evaluating the Efficacy and Safety of Momelotinib and Momelotinib Combined with Trametinib in Subjects with Metastatic KRAS-mutated Non-Small Cell Lung Cancer(NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase
  • SWOG S1206: A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), (NCI Study Number 8
  • A Randomized, Phase 3 Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small Cell Lung Adenocarcinoma
  • Use of human lung cancer specimens to create animal xenograft models of lung cancer to test novel therapies
  • Changes in Multiparametric MRI Parameters Following Stereotactic Ablative Radiotherapy in Early Stage Non-Small Cell Lung Cancer: Pilot Study
  • Living with Lung Cancer

    When you come to City of Hope, you automatically gain access to an unparalleled support services to help you and your family take each step in your lung cancer treatment. Learn more about the resources listed below at our Living with Cancer or Supportive Care Medicine sites.

    Additional Resources

    Do you know what's in cigarette smoke? Find out by watching the video below.

















    We deliver exquisite care at the leading edge of lung cancer treatment. It takes the help of a lot of caring people to make hope a reality for our patients. City of Hope was founded by individuals' philanthropic efforts over 100 years ago. Their efforts - and those of our supporters today - have built the foundation for the care we provide and the research we conduct.

    For more information on supporting the Lung and Thoracic Cancer Program, please contact Donor Relations. Or, you can make a gift to support all the research at City of Hope by donating online.

    City of Hope experts cover prevention, screening, treatment and other cancer topics on City of Hope’s Breakthrough’s blog.

    Back To Top